T-cell costimulatory blockade in organ transplantation

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 12, 2013, Pages

  Maltzman, Jonathan S ^a   Turka, Laurence A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CD134 ANTIGEN; CD137 LIGAND; CD28 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE T CELL COSTIMULATOR; INDUCIBLE T CELL COSTIMULATOR ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MITOGEN ACTIVATED PROTEIN KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CD137 ANTIGEN; CD40 LIGAND; LEUKOCYTE ANTIGEN; OX40 LIGAND; PDCD1 PROTEIN, HUMAN;

ALLOIMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CELLULAR STRESS RESPONSE; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; ORGAN TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN INTERACTION; RECEPTOR BLOCKING; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG ANTAGONISM; HISTOCOMPATIBILITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; PRIMATE; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD28; ANTIGENS, CD40; ANTIGENS, CD58; CD40 LIGAND; CTLA-4 ANTIGEN; HUMANS; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; LYMPHOCYTE ACTIVATION; OX40 LIGAND; PRIMATES; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 84889005842     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a015537     Document Type: Article

References (105)

1. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, et al. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103: 1243-1252.
2. Aoyagi T, Yamashita K, Suzuki T, Uno M, Goto R, Taniguchi M, Shimamura T, Takahashi N, Miura T, Okimura K, et al. 2009. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: Induction and maintenance therapy. Am J Transplant 9: 1732-1741.
3. Arch RH, Thompson CB. 1998. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kB. Mol Cell Biol 18: 558-565.
4. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, Sayegh MH. 1996. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci 93: 12439-12444.
5. Badell IR, Thompson PW, Turner AP, Russell MC, Avila JG, Cano JA, Robertson JM, Leopardi FV, Strobert EA, Iwakoshi NN, et al. 2012. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant 12: 126-135.
6. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
7. Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, Sharpe AH, Kuchroo VK. 2009. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol 10: 167-175.
8. Bestard O, Cassis L, Cruzado JM, Torras J, Franquesa M, Gil-Vernet S, Lucia M, Grinyó JM. 2011. Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int 24: 451-460.
9. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. 2007. TRAF proteins in CD40 signaling. Adv Exp Med Biol 597: 131-151.
10. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. 2008. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 8: 2086-2096.
11. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB. 1995. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity 3: 87-98.
12. Bour-Jordan H, Bluestone JA. 2009. Regulating the regulators: Costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 229: 41-66.
13. Charbonnier LM, Vokaer B, Lemaître PH, Field KA, Leo O, Le Moine A. 2012. CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells. Am J Transplant 12: 2313-2321.
14. Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML Jr, Greenfield EA, Baum PR, Fanslow WC, Calderhead DM, Freeman GJ, et al. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity 11: 689-698.
15. Cho HR, Kwon B, Yagita H, La S, Lee EA, Kim JE, Akiba H, Kim J, Suh JH, Vinay DS, et al. 2004. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival. Transpl Int 17: 351-361.
16. Corse E, Allison JP. 2012. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol 189: 1123-1127.
17. Croft M. 2010. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28: 57-78.
18. Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC. 2008. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: Results of 2 phase 1 studies. Blood 112: 2232-2241.
19. Davies JK, Nadler LM, Guinan EC. 2009. Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation. Sci Transl Med 1: p1ra3.
20. Dawicki W, Watts TH. 2004. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur J Immunol 34: 743-751.
21. DeBenedette MA, Wen T, Bachmann MF, Ohashi PS, Barber BH, Stocking KL, Peschon JJ, Watts TH. 1999. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 163: 4833-4841.
22. Demirci G, Amanullah F, Kewalaramani R, Yagita H, Strom TB, Sayegh MH, Li XC. 2004. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 172: 1691-1698.
23. DeSilva DR, Urdahl KB, Jenkins MK. 1991. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 147: 3261-3267.
24. {thorn} effector memory T-cells. Br J Pharmacol 161: 512-526.
25. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. 2009. Molecular mechanism and function of CD40/ CD40 L engagement in the immune system. Immunol Rev 229: 152-172.
26. Fos C, Salles A, Lang V, Carrette F, Audebert S, Pastor S, Ghiotto M, Olive D, Bismuth G, Nunès JA. 2008. ICOS ligation recruits the pp50a PI3K regulatory subunit to the immunological synapse. J Immunol 181: 1969-1977.
27. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. 1993. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II: Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 178: 1567-1575.
28. Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ. 1994. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 180: 157-163.
29. {thorn} T cell dysfunction and increase in murine gammaherpesvirus latent viral burden in the absence of 4-1BB ligand. J Immunol 178: 5227-5236.
30. Gonzalo JA, Tian J, Delaney T, Corcoran J, Rottman JB, Lora J, Al-garawi A, Kroczek R, Gutierrez-Ramos JC, Coyle AJ. 2001. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol 2: 597-604.
31. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG. 1999. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 340: 1704-1714.
32. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. 1996. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci 93: 13967-13972.
33. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356: 607-609.
34. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Muller-Berghaus G, Kroczek RA. 1998. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594.
35. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
36. Hunig T. 2012. The storm has cleared: Lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 12: 317-318.
37. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. 1999. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397: 263-266.
38. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci 99: 12293-12297.
39. Jenkins MK, Pardoll DM, Mizuguchi J, Chused TM, Schwartz RH. 1987a. Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci 84: 5409.
40. Jenkins MK, Ashwell JD, Schwartz RH. 1987b. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 140: 3324-3330.
41. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. 1987. T cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 7: 4472-4481.
42. June CH, Bluestone JA, Nadler LM, Thompson CB. 1994. The B7 and CD28 receptor families. Immunol Today 15: 321-331.
43. Kim YJ, Pollok KE, Zhou Z, Shaw A, Bohlen JB, Fraser M, Kwon BS. 1993. Novel T cell antigen 4-1BB associates with the protein tyrosine kinase pp56lck1. J Immunol 151: 1255-1262.
44. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci 94: 8789-8794.
45. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH Jr, Germond RL, Kampen RL, Patterson NB, et al. 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 5: 686-693.
46. Kopf M, Ruedl C, Schmitz N, Gallimore A, Lefrang K, Ecabert B, Odermatt B, Bachmann MF. 1999. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity 11: 699-708.
47. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349: 1907-1915.
48. Krummel MF, Allison JP. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182: 459-465.
49. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381: 434-438.
50. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, Anderson D, Cowan S, Price K, Naemura J, et al. 2005. Rational development of LEA29Y, a high affinity variant of CTLA4Ig with potent immunosuppressive properties. Am J Transpl 5: 443-453.
51. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA. 1992. Longterm survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257: 789-792.
52. Lenschow DJ, Walunas TL, Bluestone JA. 1996. CD28/B7 system of T cell costimulation. Ann Rev Immunol 14: 233-258.
53. Leung HT, Bradshaw J, Cleaveland JS, Linsley PS. 1995. Cytotoxic T lymphocyte-associated molecule-4, a highavidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem 270: 25107-25114.
54. Levisetti MG, Padrid PA, Szot GLMittal N, Meehan M, Wardrip CL, Gray GS, Bruce DS, Thistlethwaite JR, Bluestone JA. 1997. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 159: 5187-5191.
55. Li Y, Li XC, Wells AD, Zheng XX, Turka LA, Strom TB. 1999. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5: 1298-1302.
56. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA. 1993. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 178: 1801-1806.
57. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB. 1989. Regulation of lyphokine messenger RNA stability by surface-mediated T cell activation pathway. Science 244: 339.
58. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174: 561-569.
59. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257: 792-795.
60. Lowe M, Badell IR, Thompson P, Martin B, Leopardi F, Strobert E, Price AA, Abdulkerim HS, Wang R, Iwakoshi NN, et al. 2012. A novel monoclonal antibody to CD40 prolongs islet allograft survival. Am J Transplant 12: 2079-2087.
61. McAdam AJ, Greenwald RJ, Levin MA, Chernova T, Malenkovich N, Ling V, Freeman GJ, Sharpe AH. 2001. ICOS is critical for CD40-mediated antibody class switching. Nature 409: 102-105.
62. Oestreich KJ, Yoon H, Ahmed R, Boss JM. 2008. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 181: 4832-4839.
63. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. 2002. Dendritic cell development and survival require distinct NF-kB subunits. Immunity 16: 257-270.
64. Ozkaynak E, Gao W, Shemmeri N, Wang C, Gutierrez-Ramos JC, Amaral J, Qin S, Rottman JB, Coyle AJ, Hancock WW. 2001. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2: 591-596.
65. Ozkaynak E, Wang L, Goodearl A, McDonald K, Qin S, O'Keefe T, Duong T, Smith T, Gutierrez-Ramos JC, Rottman JB, et al. 2002. Programmed death-1 targeting can promote allograft survival. J Immunol 169: 6546-6553.
66. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL. 2003. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol 171: 166-174.
67. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25: 9543-9553.
68. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. 1994. Transplantation tolerance induced by CTLA4-Ig. Transplantation 57: 1701-1706.
69. Poirier N, Azimzadeh AM, Zhang T, Dilek N, Mary C, Nguyen B, Tillou X, Wu G, Reneaudin K, Hervouet J, et al. 2010. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2: 17ra10.
70. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS. 1993. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 150: 771-781.
71. Pollok KE, Kim YJ, Hurtado J, Zhou Z, Kim KK, Kwon BS. 1994.4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-m-primed splenic B cells. Eur J Immunol 24: 367-374.
72. Pullen SS, Labadia ME, Ingraham RH, McWhirter SM, Everdeen DS, Alber T, Crute JJ, Kehry MR. 1999. Highaffinity interactions of tumor necrosis factor receptorassociated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 38: 10168-10177.
73. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. 2004. CD40/ CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22: 307-328.
74. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, et al. 2011. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600-603.
75. Riella LV, Liu T, Yang J, Chock S, Shimizu T, Mfarrej B, Batal I, Xiao X, Sayegh MH, Chandraker A. 2012. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant 12: 846-855.
76. Rottman JB, Smith T, Tonra JR, Ganley K, Bloom T, Silva R, Pierce B, Gutierrez-Ramos JC, Ozkaynak E, Coyle AJ. 2001. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2: 605-611.
77. Rudd CE, Schneider H. 2003. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 3: 544-556.
78. Saiki H, Suzuki J, Kosuge H, Haraguchi G, Ishihara T, Haga T, Maejima Y, Isobe M, Uede T. 2008. Blockade of the 41BB pathway attenuates graft arterial disease in cardiac allografts. Int Heart J 49: 105-118.
79. {thorn} immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440.
80. {thorn} Treg. J Immunol 189: 5985-5994.
81. Shiratori T, Miyatake S, Ohno H, Nakaseko C, Isono K, Bonifacino JS, Saito T. 1997. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 6: 583-589.
82. Simpson TR, Quezada SA, Allison JP. 2010. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol 22: 326-332.
83. Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M. 2004. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat Immunol 5: 150-158.
84. Song J, So T, Cheng M, Tang X, Croft M. 2005. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 22: 621-631.
85. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028.
86. Tan JT, Whitmire JK, Ahmed R, Pearson TC, Larsen CP. 1999.4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J Immunol 163: 4859-4868.
87. Tan JT, Whitmire JK, Murali-Krishna K, Ahmed R, Altman JD, Mittler RS, Sette A, Pearson TC, Larsen CP. 2000. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol 164: 2320-2325.
88. Tan AH, Wong SC, Lam KP. 2006. Regulation of mouse inducible costimulator (ICOS) expression by Fyn-NFATc2 and ERK signaling in T cells. J Biol Chem 281: 28666-28678.
89. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
90. Tran HM, Nickerson PW, Restifo AC, Ivis-Woodward MA, Patel A, Allen RD, Strom TB, O'Connell PJ. 1997. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol 159: 2232-2239.
91. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, Gibson ML, Zheng XG, Myrdal S, Gordon D, et al. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci 89: 11102-11105.
92. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.
93. Valk E, Leung R, Kang H, Kaneko K, Rudd CE, Schneider H. 2006. T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor. Immunity 25: 807-821.
94. Van den Eertwegh AJ, Noelle RJ, Roy M, Shepherd DM, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E. 1993. In vivo CD40-gp39 interactions are essential for thymusdependent humoral immunity. I: In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 178: 1555-1565.
95. {thorn} Tregs. Blood 110: 2501-2510.
96. Walker LS, Sansom DM. 2011. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 11: 852-863.
97. {thorn} T cells. Am J Transplant 3: 543-551.
98. Wang L, Han R, Hancock WW. 2007. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. Eur J Immunol 37: 2983-2990.
99. Wang CJ, Kenefeck R, Wardzinski L, Attridge K, Manzotti C, Schmidt EM, Qureshi OS, Sansom DM, Walker LS. 2012. Cutting edge: Cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J Immunol 189: 1118-1122.
100. Weaver TA, Charafeddine AH, Agarwal A, Turner AP, Russell M, Leopardi FV, Kampen RL, Stempora L, Song M, Larsen CP, et al. 2009. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 15: 746-749.
101. Wells AD, Li XC, Li Y, Walsh M, Zheng XX, Wu Z, Nuñez G, Tang A, Sayegh M, Hancock WW, Strom TB, Turka LA. 1999. Requirement for T cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 5: 1303-1307.
102. Yang J, Riella LV, Boenisch O, Popoola J, Robles S, Watanabe T, Vanguri V, Yuan X, Guleria I, Turka LA, et al. 2009. Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model. Am J Transplant 9: 2837-2844.
103. Ye H, Park YC, Kreishman M, Kieff E, Wu H. 1999. The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell 4: 321-330.
104. Zhang T, Fresnay S, Welty E, Sangrampurkar N, Rybak E, Zhou H, Cheng XF, Feng Q, Avon C, Laaris A, et al. 2011. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 11: 1599-1609.
105. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA. 2013. An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest 123: 580-593.